AR091724A1 - Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica - Google Patents
Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceuticaInfo
- Publication number
- AR091724A1 AR091724A1 ARP130102454A AR091724A1 AR 091724 A1 AR091724 A1 AR 091724A1 AR P130102454 A ARP130102454 A AR P130102454A AR 091724 A1 AR091724 A1 AR 091724A1
- Authority
- AR
- Argentina
- Prior art keywords
- fampridine
- laquinimod
- multiple sclerosis
- treatment
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Método de tratamiento de un sujeto que sufre de esclerosis múltiple o que presenta un síndrome clínicamente aislado que comprende administrar al sujeto fampridina como una terapia adyuvante o en combinación con laquinimod. Un envase que comprende laquinimod y fampridina para tratar a un sujeto afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado. Fampridina para su uso como una terapia adyuvante o en combinación con laquinimod en el tratamiento de un sujeto que sufre de esclerosis múltiple o que presenta un síndrome clínicamente aislado. Composición farmacéutica que comprende laquinimod y fampridina para su uso en el tratamiento de un sujeto afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado. Uso de laquinimod y fampridina en la preparación de una combinación para tratar a un sujeto que sufre de esclerosis múltiple o que presenta un síndrome clínicamente aislado. Reivindicación 59: La composición farmacéutica de cualquiera de las reivindicaciones 54 - 57, caracterizada porque la cantidad de laquinimod en la composición es de 0,25 - 2,0 mg. Reivindicación 68: La composición farmacéutica de cualquiera de las reivindicaciones 54 - 66, caracterizada porque la cantidad de fampridina en la composición es de 1,0 - 20 mg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670758P | 2012-07-12 | 2012-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091724A1 true AR091724A1 (es) | 2015-02-25 |
Family
ID=49914160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102454 AR091724A1 (es) | 2012-07-12 | 2013-07-10 | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica |
Country Status (16)
Country | Link |
---|---|
US (2) | US20140017226A1 (es) |
EP (1) | EP2872217A4 (es) |
JP (1) | JP2015522077A (es) |
KR (1) | KR20150038072A (es) |
CN (1) | CN104582793A (es) |
AR (1) | AR091724A1 (es) |
AU (1) | AU2013290181A1 (es) |
BR (1) | BR112015000616A2 (es) |
CA (1) | CA2873229A1 (es) |
EA (1) | EA201590191A1 (es) |
HK (1) | HK1209672A1 (es) |
IL (1) | IL236230A0 (es) |
MX (1) | MX2015000485A (es) |
TW (1) | TW201408300A (es) |
UY (1) | UY34896A (es) |
WO (1) | WO2014011827A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201491460A1 (ru) | 2012-02-03 | 2015-01-30 | Тева Фармасьютикал Индастриз Лтд. | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα |
AR090073A1 (es) | 2012-02-16 | 2014-10-15 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
KR20150091077A (ko) | 2012-11-07 | 2015-08-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드의 아민염 |
WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
US20150306088A1 (en) * | 2014-04-29 | 2015-10-29 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
GB2540163A (en) * | 2015-07-07 | 2017-01-11 | Univ London Queen Mary | Combination therapy for treating multiple sclerosis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9726339D0 (en) * | 1997-12-13 | 1998-02-11 | Zeneca Ltd | Human-derived tissue-specific potassium channel |
US20090082471A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
ES2329327B1 (es) * | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
US20100061935A1 (en) * | 2008-09-10 | 2010-03-11 | Acorda Therapeutics, Inc. | Methods of using sustained release aminopyridine compositions |
EP3028572A1 (en) * | 2009-06-19 | 2016-06-08 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
US8889627B2 (en) * | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
-
2013
- 2013-07-09 UY UY0001034896A patent/UY34896A/es not_active Application Discontinuation
- 2013-07-10 AR ARP130102454 patent/AR091724A1/es unknown
- 2013-07-10 TW TW102124792A patent/TW201408300A/zh unknown
- 2013-07-11 WO PCT/US2013/050001 patent/WO2014011827A1/en active Application Filing
- 2013-07-11 JP JP2015521792A patent/JP2015522077A/ja active Pending
- 2013-07-11 EA EA201590191A patent/EA201590191A1/ru unknown
- 2013-07-11 EP EP13816075.9A patent/EP2872217A4/en not_active Withdrawn
- 2013-07-11 MX MX2015000485A patent/MX2015000485A/es unknown
- 2013-07-11 AU AU2013290181A patent/AU2013290181A1/en not_active Abandoned
- 2013-07-11 CN CN201380037036.0A patent/CN104582793A/zh active Pending
- 2013-07-11 KR KR1020157003858A patent/KR20150038072A/ko not_active Application Discontinuation
- 2013-07-11 CA CA2873229A patent/CA2873229A1/en not_active Abandoned
- 2013-07-11 BR BR112015000616A patent/BR112015000616A2/pt not_active IP Right Cessation
- 2013-07-11 US US13/939,306 patent/US20140017226A1/en not_active Abandoned
-
2014
- 2014-12-14 IL IL236230A patent/IL236230A0/en unknown
-
2015
- 2015-10-19 HK HK15110240.0A patent/HK1209672A1/xx unknown
-
2016
- 2016-04-21 US US15/135,280 patent/US20160235735A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104582793A (zh) | 2015-04-29 |
MX2015000485A (es) | 2015-04-08 |
WO2014011827A1 (en) | 2014-01-16 |
TW201408300A (zh) | 2014-03-01 |
US20140017226A1 (en) | 2014-01-16 |
CA2873229A1 (en) | 2014-01-16 |
JP2015522077A (ja) | 2015-08-03 |
KR20150038072A (ko) | 2015-04-08 |
EP2872217A1 (en) | 2015-05-20 |
HK1209672A1 (en) | 2016-04-08 |
UY34896A (es) | 2014-02-28 |
EP2872217A4 (en) | 2016-03-16 |
EA201590191A1 (ru) | 2015-06-30 |
IL236230A0 (en) | 2015-01-29 |
BR112015000616A2 (pt) | 2017-06-27 |
AU2013290181A1 (en) | 2015-02-26 |
US20160235735A1 (en) | 2016-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
BR112014008731A2 (pt) | tratamento de esclerose múltipla com combinação de laquinimode e fingolimode | |
MX2014001050A (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. | |
WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
BR112015001847A8 (pt) | Composições e tratamento para doenças e distúrbios nos olhos | |
MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
EA201270747A1 (ru) | Композиции и способы для профилактики и лечения ран | |
EA201071350A1 (ru) | Композиции и способы для лечения воспаления роговицы | |
BR112015007095A8 (pt) | derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados | |
WO2013038200A3 (en) | Neurodevelopmental disorders | |
MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |